Saurabh Agarwal

Employment

• St. John's University Assistant Professor
  2018 - Present
• Baylor College of Medicine Instructor
  2015 - Present
• Baylor College of Medicine Postdoctoral Fellow
  2011 - Present
• INSERM Postdoctoral Fellow
  2009 - 2010

Education

• University of Lucknow PhD
  2003 - 2010
• Jiwaji University M.S.
  2001 - 2003

Projects & Funding

Projects & funding information is unavailable.

Publications (64)

• Autophagy Activation Drives Apoptosis and Inhibits High-Risk Neuroblastoma Growth (Abstract ID: 229835)
  The Journal of Pharmacology and Experimental Therapeutics 2026 DOI: 10.1016/j.jpet.2026.103932
  +Save
• Direct Targeting of the JAK2/STAT3 Pathway Inhibits Cancer Stemness and Neuroblastoma Growth (Abstract ID: 222244)
  The Journal of Pharmacology and Experimental Therapeutics 2026 DOI: 10.1016/j.jpet.2026.103858
  +Save
• From Hits to Leads: High-Throughput Screening Identifies STAT3-Targeted Therapeutics for High-Risk Neuroblastoma (Abstract ID: 229183)
  The Journal of Pharmacology and Experimental Therapeutics 2026 DOI: 10.1016/j.jpet.2026.103863
  +Save
• Pharmacological Dual Targeting of PI3K and HDAC2 as a Rational Therapeutic Approach for High-Risk Medulloblastoma (Abstract ID: 226469)
  The Journal of Pharmacology and Experimental Therapeutics 2026 DOI: 10.1016/j.jpet.2026.104204
  +Save
• Targeting Mitochondrial ROS Restores Redox Balance and Inhibits Neuroblastoma Growth (Abstract ID: 228607)
  The Journal of Pharmacology and Experimental Therapeutics 2026 DOI: 10.1016/j.jpet.2026.103850
  +Save
• 3D Spheroid Model: A Methodological Approach for Advancing Cancer and Immunology Research
  Methods in Molecular Biology 2026 DOI: 10.1007/978-1-0716-4901-5_10
  +Save
• Golvatinib (E7050) restores chemosensitivity in multidrug-resistant cancer cells by inhibiting ABCG2 transporter
  Pathology - Research and Practice 2026 DOI: 10.1016/j.prp.2026.156663
  +Save
• Striking at Survivin: YM-155 Inhibits High-Risk Neuroblastoma Growth and Enhances Chemosensitivity
  Cancers 2025 DOI: 10.3390/cancers17193221
  +Save
• Dual Targeting of PI3K/mTOR Oncogenic Pathway Is a Promising Therapeutic Strategy for High-Risk Neuroblastoma (Abstract ID: 170196)
  The Journal of Pharmacology and Experimental Therapeutics 2025 DOI: 10.1016/j.jpet.2024.100568
  +Save
• PRMT5 inhibition is a promising therapeutic strategy for high-risk neuroblastoma
  Cancer Research 2025 DOI: 10.1158/1538-7445.am2025-6826
  +Save